ES2173237T3 - Procedimiento de fabricacion de anticuerpos monoclonales humanos y su uso. - Google Patents

Procedimiento de fabricacion de anticuerpos monoclonales humanos y su uso.

Info

Publication number
ES2173237T3
ES2173237T3 ES96117361T ES96117361T ES2173237T3 ES 2173237 T3 ES2173237 T3 ES 2173237T3 ES 96117361 T ES96117361 T ES 96117361T ES 96117361 T ES96117361 T ES 96117361T ES 2173237 T3 ES2173237 T3 ES 2173237T3
Authority
ES
Spain
Prior art keywords
derivative
antibodies
human monoclonal
monoclonal antibodies
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96117361T
Other languages
English (en)
Inventor
Georg Wilhelm Prof Bornkamm
Dirk Priv Doz Dr Eick
Bettina Dr Kempkes
Nicola Maria Jochner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Application granted granted Critical
Publication of ES2173237T3 publication Critical patent/ES2173237T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

DE ACUERDO CON LA INVENCION SE PREPARA UN PROCEDIMIENTO PARA LA OBTENCION DE ANTICUERPOS MONOCLONALES HUMANOS CON LAS SIGUIENTES ETAPAS: A) INMORTALIZACION DE CELULAS B QUE PRODUCEN ANTICUERPOS HUMANOS CON UN VIRUS DE EPSTEIN-BARR O UN DERIVADO DE EL, B) ESCRUTINIO EN LAS CELULAS INMORTALES DE SU ESPECIFICIDAD PARA EL ANTIGENO DESEADO Y AISLAMIENTO DE CLONES CELULARES, QUE PRODUCEN LOS CORRESPONDIENTES ANTICUERPOS, C) RECUPERACION DE LOS ANTICUERPOS DESEADOS DE LOS CULTIVOS; ESTE PROCEDIMIENTO SE CARACTERIZA PORQUE D) SE UTILIZA UN VIRUS DE EPSTEIN-BARR O UN DERIVADO DE EL CON UN GEN CONDICIONAL DEL ANTIGENO 2 NUCLEAR DEL VIRUS DE EPSTEINBARR (EBNA2) O UN DERIVADO DE EL, EN UNION FUNCIONAL, ESTE GEN SE CONECTA AL MENOS PARCIALMENTE PARA LA INMORTALIZACION, Y E) EL GEN EBNA2 O SU DERIVADO SE DESCONECTA AL MENOS PARCIALMENTE ANTES DE RECUPERAR EL ANTICUERPO.
ES96117361T 1995-11-09 1996-10-29 Procedimiento de fabricacion de anticuerpos monoclonales humanos y su uso. Expired - Lifetime ES2173237T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541844A DE19541844C1 (de) 1995-11-09 1995-11-09 Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung

Publications (1)

Publication Number Publication Date
ES2173237T3 true ES2173237T3 (es) 2002-10-16

Family

ID=7777063

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96117361T Expired - Lifetime ES2173237T3 (es) 1995-11-09 1996-10-29 Procedimiento de fabricacion de anticuerpos monoclonales humanos y su uso.

Country Status (6)

Country Link
US (1) US5798230A (es)
EP (1) EP0773228B1 (es)
AT (1) ATE215563T1 (es)
DE (2) DE19541844C1 (es)
DK (1) DK0773228T3 (es)
ES (1) ES2173237T3 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19740571C1 (de) * 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
DE19816116C2 (de) * 1998-04-09 2000-06-29 Gsf Forschungszentrum Umwelt Verfahren zur Immortalisation von Zellen mit Hilfe konditional transformierter Helferzellen
JP2002524529A (ja) 1998-09-14 2002-08-06 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法
EP1119368A2 (en) 1999-03-03 2001-08-01 Biogen, Inc. Methods of modulating lipid metabolism and storage
PT1173201E (pt) 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
EP1181054A1 (en) 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US7241443B1 (en) * 1999-07-15 2007-07-10 Camas Incorporated Immunogen adherence inhibitor and method of making and using same
NZ519447A (en) 1999-12-16 2004-03-26 Biogen Inc Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE60236735D1 (de) 2001-04-13 2010-07-29 Biogen Idec Inc Antikörper gegen vla-1
ATE555194T1 (de) 2001-12-18 2012-05-15 Cancer Rec Tech Ltd Methode zur herstellung von proliferierenden und differenzierenden zelllinien
GB2387599B (en) * 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
CA2514117A1 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
AU2004249673A1 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
CA2548813A1 (en) * 2003-12-08 2005-06-23 Morphotek, Inc. Antibodies that specifically bind pms2
JP4485475B2 (ja) * 2004-02-12 2010-06-23 独立行政法人科学技術振興機構 核内レセプターのアゴニスト・アンタゴニスト検出用プローブとそれを用いた核内レセプターに対するアゴニストおよびアンタゴニストのスクリーニング方法
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CA2587597A1 (en) 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
NZ581497A (en) * 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
EP1819736B1 (en) * 2004-12-03 2010-08-04 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
KR101213894B1 (ko) 2005-03-02 2012-12-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
EP1863519B1 (en) 2005-03-31 2013-09-25 The General Hospital Corporation Modulating hgf/hgfr activity for treating lymphodema
DK2645106T4 (da) 2005-04-04 2024-12-02 Biogen Ma Inc Fremgangsmåder til evaluering af et immunrespons på et terapeutisk middel
US20060230734A1 (en) * 2005-04-14 2006-10-19 Deere & Company, A Delaware Corporation Twin belt mule drive
CA2607444C (en) 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1871809A2 (en) * 2005-04-22 2008-01-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
TWI428143B (zh) 2006-01-18 2014-03-01 Gen Hospital Corp 增加淋巴功能之方法
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
DE202006007499U1 (de) * 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
DE202006007590U1 (de) * 2006-05-12 2006-12-14 Osaka University Verwendung einer Zusammensetzung, die Sema7A- und VLA-1-Interaktion inhibiert, zum Behandeln von Cytokin-vermittelten Erkrankungen
PL2034830T3 (pl) 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
EP2056709A4 (en) 2006-08-11 2013-05-01 Univ New Jersey Med DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
EP2134855A4 (en) 2007-03-12 2011-01-05 Dana Farber Cancer Inst Inc USES OF FANCI AND FANCI MODULATING AGENTS IN PROGNOSIS, DIAGNOSIS AND CANCER THERAPY
EP2583551A1 (en) * 2007-03-13 2013-04-24 National Jewish Health Methods for generation of antibodies
ME00832B (me) 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
CA2682726C (en) * 2007-04-05 2017-05-09 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
JP5116842B2 (ja) 2007-04-27 2013-01-09 ザイモジェネティクス， インコーポレイテッド ＩＬ−１７ＡおよびＩｌ−１７Ｆの両方に結合する抗体ならびにそれを使用する方法
EP2150564A2 (en) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
NZ595526A (en) * 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
AU2008284015B2 (en) 2007-08-03 2014-05-15 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
CA2699988A1 (en) 2007-08-16 2009-02-26 Christine Dierks Methods and compositions for treating cancers
CA2718321A1 (en) * 2008-03-27 2009-10-01 Dimiter S. Dimitrov Human anti-mesothelin monoclonal antibodies
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
WO2009149021A2 (en) 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
JP2013525260A (ja) * 2009-04-17 2013-06-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 急性骨髄性白血病を治療するための組成物および方法
ES2666372T3 (es) 2009-10-11 2018-05-04 Biogen Ma Inc. Ensayos relacionados con anti-VLA-4
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
HRP20171045T1 (hr) 2010-04-16 2017-10-06 Biogen Ma Inc. Protutijela anti-vla-4
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
WO2012033987A2 (en) 2010-09-09 2012-03-15 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
EP2724157B1 (en) 2011-06-27 2017-03-08 Valneva Method for screening cells
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
ES2731757T3 (es) 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
CN103196817A (zh) * 2013-04-10 2013-07-10 哈尔滨体育学院 一种优秀冰雪运动员eb病毒转化细胞凋亡鉴定方法
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体

Also Published As

Publication number Publication date
DK0773228T3 (da) 2002-07-22
US5798230A (en) 1998-08-25
DE59609000D1 (de) 2002-05-08
EP0773228A1 (de) 1997-05-14
EP0773228B1 (de) 2002-04-03
DE19541844C1 (de) 1997-07-24
ATE215563T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
ES2173237T3 (es) Procedimiento de fabricacion de anticuerpos monoclonales humanos y su uso.
NO803658L (no) Hybridcellelinje for fremstilling av komplementfikserende monoklonalt antistoff til humane undertrykker t-celler, selve antistoffet og fremgangsmaater for dets fremstilling
IL114444A (en) Kit for inducing immune response against a tumor or a disease caused by an infectious agent
ES2110411T3 (es) Metodos para cultivar el virus de la hepatitis c (hcv) en lineas celulares de linfocitos b o t.
ES2188583T3 (es) Polipeptidos para el virus de la hepatitis c (hcv).
DK0752869T3 (da) Celler med talrige ændrede epitoper på et overfladeantigen til anvendelse ved transplantationen
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK180580A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
ES2139607T3 (es) Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.
ATE13317T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozytantigen; antikoerper und verfahren zu seiner herstellung; diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
BR9610802A (pt) Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
DK0853633T3 (da) Humant monoklonalt antistof imod hepatitis B virus overfladeantigen (HBVsAg)
ES2130121T3 (es) Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva.
PT912611E (pt) Anticorpos monoclonais humanos para o anti-gene de superficie da hepatite b
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
ATE244762T1 (de) Säugetier - expressionssysteme für hüllenprotingene des hepatitit - c - virus
ATE12660T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches thymozytantigen, antikoerper und verfahren zu seiner herstellung, diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
EP1013757A3 (en) Attenuated forms of bovine viral diarrhea virus
ES2064349T3 (es) Inmunoglobulinas humanas especificas del antigeno relacionado con el cancer e hibridomas humanos-humanos que pueden producir estas inmunoglobulinas humanas.
DK1002092T3 (da) Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf
ES2118129T3 (es) Anticuerpos monoclonales contra las regiones de cubierta putativas del virus vhc y procedimientos de utilizacion de estos.
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
DE60141832D1 (de) Humaner monoklonaler antikörper gegen das hepatitis c virus e2 glykoprotein
ES8701837A1 (es) Procedimiento para producir una composicion viral ateunada viva uniforme de hepatitis a.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 773228

Country of ref document: ES